Wednesday, 30 September 2026 11:30 AM
Class Action
NEW YORK CITY, NY / ACCESS Newswire / September 30, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into uniQure N.V. ("uniQure N.V.") (NASDAQ:QURE) concerning potential violations of the federal securities laws.
Shares of uniQure N.V. opened down nearly 40% on September 29, 2026, following the release of mixed 48-month clinical data for AMT-130, its gene therapy for Huntington's disease. Although the therapy continued to show evidence of slowing disease progression, the four-year results failed to meet a key statistical measure and appeared less compelling than earlier three-year data that had been utilized as the basis for a Biologics License Application (BLA). This disappointed investors and raised concerns regarding the treatment's long-term durability and its prospects for regulatory approval.
If you suffered a loss on your uniQure N.V. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
SOURCE: Levi & Korsinsky, LLP